Research Topics
| Douglas S GoodinSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
The genetic and environmental bases of complex human-disease: extending the utility of twin-studiesDouglas S Goodin
Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 7:e47875. 2012..Also, susceptible men (compared to susceptible women) have a lower threshold, a greater hazard-rate, or both in response to the environmental factors involved in MS pathogenesis...- Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialD S Goodin
Department of Neurology, University of California, San Francisco, CA, USA
Neurology 78:1315-22. 2012.... - Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSDouglas S Goodin
Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 6:e22444. 2011..For example, although disease-modifying therapy in MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function remains uncertain... 
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosisDouglas S Goodin
University of California, San Francisco, San Francisco, CA 94143 0114, USA
J Neurol Neurosurg Psychiatry 83:282-7. 2012..Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established...- Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin
University of California at San Francisco, CA 94143 0114, USA
Mult Scler 18:181-95. 2012..The frequency and impact of neutralizing antibodies (NAbs) to interferon beta-1b (IFNβ-1b) on clinical and radiographic outcomes is controversial... - The genetic basis of multiple sclerosis: a model for MS susceptibilityDouglas S Goodin
Department of Neurology, University of California, San Francisco, CA, USA
BMC Neurol 10:101. 2010..MS-pathogenesis is known to involve both multiple environmental events, and several independent genetic risk-factors... - Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episodeD S Goodin
Department of Neurology, University of California, San Francisco, CA 94143 0114, USA
Mult Scler 15:1175-82. 2009.... - Disease-modifying therapy in multiple sclerosis: update and clinical implicationsDouglas S Goodin
Department of Neurology, University of California, San Francisco, CA, USA
Neurology 71:S8-13. 2008..Second, high-dose IFN beta-1a or IFN beta-1b subcutaneous has a similar clinical impact to glatiramer acetate, although IFN beta subcutaneous is superior on some MRI outcome measures... 
Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisD S Goodin
Department of Neurology, University of California, San Francisco 94143 0114, USA
J Int Med Res 35:173-87. 2007..Our results suggest that NAbs are not responsible for poor clinical responses and that NAb status is of little clinical value. These findings will need to be confirmed in a large independent study...- Multiple Sclerosis: The Big Questions- The MS Forum WorkshopDs Goodin
Douglas S Goodin MS Center at the University of California San Francisco 350 Parnassus Avenue Suite 908 San Francisco CA 94117 USA Tel 415 514 2464 Fax 415 514 2470 E mail
Int MS J 17:100-7. 2011..Highlights were presentations on the controversial theory of venous obstruction as a cause of MS and updates on promising oral treatments, particularly fingolimod, cladribine and teriflumomide... - The causal cascade to multiple sclerosis: a model for MS pathogenesisDouglas S Goodin
Department of Neurology, University of California San Francisco, San Francisco, California, USA
PLoS ONE 4:e4565. 2009..The first acts near birth, the second acts during childhood, and the third acts long thereafter. Two candidate factors (vitamin D deficiency and Epstein-Barr viral infection) seem well suited to the first two environmental events... - Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MSA T Reder
Department of Neurology, University of Chicago, Chicago, IL 60637, USA
Neurology 74:1877-85. 2010..The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments... - Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypesJeffrey M Gelfand
University of California, San Francisco Department of Neurology, Multiple Sclerosis Center, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 7:e36847. 2012.... - Switching multiple sclerosis patients with breakthrough disease to second-line therapyTamara Castillo-Trivino
Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA
PLoS ONE 6:e16664. 2011..The effect of natalizumab monotherapy in patients with breakthrough disease is unknown... - Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility lociNikolaos A Patsopoulos
Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
Ann Neurol 70:897-912. 2011..To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci... - Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-responseDouglas S Goodin
Department of Neurology Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
J Neurol 251:v50-v56. 2004..It is the purpose of this manuscript, therefore, to provide an overview of this process using examples from two recently completed assessments on disease-modifying therapies in multiple sclerosis... - Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errorsDouglas S Goodin
Department of Neurology, Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, California 94143 0114, USA
J Neurol 251:v3-v11. 2004.... - Quality of life in multiple sclerosis is associated with lesion burden and brain volume measuresE M Mowry
Department of Neurology, University of California, San Francisco, 94117, USA
Neurology 72:1760-5. 2009..Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is unclear whether HRQOL is associated with white matter lesion burden or measures of brain atrophy... - Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndromeD T Okuda
Department of Neurology, University of California San Francisco, UCSF Multiple Sclerosis Center, San Francisco, CA 94117, USA
Neurology 72:800-5. 2009..Routinely encountered in clinical practice, the natural history or evolution of such individuals with respect to their risk of developing multiple sclerosis (MS) is unclear... - Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosisD S Goodin
Department of Neurology, University of California, San Francisco, Calif 94143 0114, USA
Neuroepidemiology 18:53-63. 1999..This review considers several recently published therapeutic trials in order to exemplify some of the difficulties that commonly arise in this area of clinical research... - Therapeutic developments in multiple sclerosisD S Goodin
Department of Neurology, M 794, University of California, San Francisco, CA 94143 0114, USA
Expert Opin Investig Drugs 9:655-70. 2000..Moreover, it also seems likely that, increasingly, therapeutic strategies that enhance or promote myelin repair will become a major focus of clinical research in this area... - Treatment of multiple sclerosis with human beta interferonD S Goodin
Department of Neurology, University of California at San Francisco, Fort Miley Veterans Administration Hospital, 94121, USA
Int MS J 12:96-108. 2005..Future therapeutic developments in MS will be fuelled by our increasing understanding of the physical and biological roles of the interferons, in health and in MS pathogenesis... - Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose responseD S Goodin
Department of Neurology, University of California, San Francisco 94143 0114, USA
Drugs 61:1693-703. 2001..As a result, it is possible that the apparent dose-response observed in these clinical trials may be due, in part, to the more frequent dose administration schedule rather than the total weekly dose... - Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosisB A C Cree
Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
Neurology 63:2039-45. 2004..African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals... - Results of using a wireless inertial measuring system to quantify gait motions in control subjectsIris Tien
Center for Information Technology Research in the Interest of Society, University of California, Berkeley, CA 94720, USA
IEEE Trans Inf Technol Biomed 14:904-15. 2010..It also presents initial results from control subjects, focusing on understanding the data recorded by the shoe-mounted sensor to quantify relevant gait-related motions... - Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisSergio E Baranzini
Department of Neurology, University of California, San Francisco, CA 94143 0435, USA
Hum Mol Genet 18:767-78. 2009..Gene ontology-based analysis shows a functional dichotomy between genes involved in the susceptibility pathway and those affecting the clinical phenotype... - Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosisDouglas S Goodin
Department of Neurology, University of California, San Francisco, CA 94121, USA Email
Curr Med Res Opin 23:2823-32. 2007.... - Electrical brain events associated with awareness of errorsJeffrey W Ralph
Department of Neurology, Rm M 794, University of California, San Francisco, CA 94143 0114, USA
Brain Res 1251:213-22. 2009..The neurophysiological correlates of mental activity and awareness are important to define, as they permit the objective study of these psychological phenomena... - Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?Douglas S Goodin
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0114, USA
Ann Neurol 59:597-605. 2006.... - Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of cautionJacqueline F Marcus
Department of Neurology, University of California, San Francisco, 350 Parnassus Ave, 908, PO Box 0114, San Francisco, CA 94143, USA
Arch Neurol 69:129-32. 2012..To describe a patient with multiple sclerosis (MS) who developed severe hypercalcemia, attributed to the additive effect of 5500 IU of cholecalciferol and 2020 mg of calcium daily... - Pilot trial of low-dose naltrexone and quality of life in multiple sclerosisBruce A C Cree
Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
Ann Neurol 68:145-50. 2010..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients... - Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scorePhilip L De Jager
Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
Lancet Neurol 8:1111-9. 2009..We investigated the usefulness of an aggregate measure of risk of MS that is based on genetic susceptibility loci. We also assessed the added effect of environmental risk factors that are associated with susceptibility for MS... - Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin
University of California, San Francisco, CA, USA
Neurology 68:977-84. 2007.... - Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measuresD T Okuda
UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA
Brain 132:250-9. 2009.... - HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease courseL F Barcellos
Department of Neurology, University of California at San Francisco, San Francisco, CA, USA
Am J Hum Genet 72:710-6. 2003..Concepts of the molecular mechanisms that underlie linkage and association of the human leukocyte antigen (HLA) region to MS need to be revised to accommodate these data... - Neuromyelitis opticaBruce A C Cree
Department of Neurology, University of California San Francisco, USA
Semin Neurol 22:105-22. 2002..The history of NMO, its nosology, associations with other diseases, and current concepts of its pathogenesis and treatment is reviewed in this article... - Evidence-based medicineD S Goodin
Department of Neurology, University of California, San Francisco, USA
Int MS J 12:94-5. 2005..Its relative objectivity means that evidence-based medicine can be a powerful tool for practising physicians. As a result, it is important for them to become familiar with this analytical method... - Long-latency cerebral event-related potentials in multiple sclerosisJ C Aminoff
Department of Neurology, University of California, San Francisco 94143-0114, USA
J Clin Neurophysiol 18:372-7. 2001..The recording of event-related potentials may thus provide a useful tool, not only as an objective measure of cognitive function in patients with MS, but also as an aid in the evaluation of response to treatment... - Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centreD S Goodin
J Neurol 253:947-8; author reply 949. 2006 - The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyE M Frohman
University of Texas Southwestern Medical Center at Dallas, USA
Neurology 61:602-11. 2003..By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely... - The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin
Therapeutics and Technology Assessment Subcommittee, American Academy of Neurology, St. Paul, MN 55116, USA
Neurology 61:1332-8. 2003.... - Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE TrialH Panitch
University of Vermont College of Medicine, Burlington, VT 05401, USA
Neurology 59:1496-506. 2002..Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial... - Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesD S Goodin
Neurology 58:169-78. 2002 - Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin
University of California at San Francisco, USA
Neurology 71:766-73. 2008..The PML risk in a pooled clinical trial cohort has been estimated to be 1 person for every 1,000 patients treated for an average of 17.9 months, although this figure could change in either direction with more experience with the drug...